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Purpose
Herpes zoster is reported to be one of the most com-
mon viral infections affecting Systemic Lupus Erythema-
tosus (SLE) patients. The aim of the present study is to
provide a descriptive analysis of the clinical features
seen in childhood-onset SLE (cSLE) patients affected by
herpes zoster.
Methods
A retrospective chart review of cSLE patients at one ter-
tiary care center was conducted. Among cSLE patients
followed between 1998 and January 2010, 9 patients
who were diagnosed and treated for herpes zoster were
identified. Data extracted included demographic and
clinical features of cSLE disease at presentation, disease
activity, medication and immunization history, and
course of zoster infection.
Results
A total of 170 patients with childhood-onset SLE were
treated in the defined time period. 9 (5.3%) of cSLE
patients developed one or more herpes zoster virus (HZV)
infections. There were 8 females (89%), and the mean age
of cSLE at diagnosis of HZV was 12.75 yr (± 3.18). There
were 4 Hispanic patients, 3 African-American, 1 Asian,
and 1 Caucasian. Distribution of skin lesions included the
chest in 2 patients (T4 and T6 dermatomes, respectively),
abdomen in 2, and 2 each in the upper and lower extremi-
ties. All patients had resolution of lesions within 4 weeks
and there was no mortality. Two patients had visceral
involvement, 1 with meningeal spread and another with
pancreatitis. Two patients experienced postherpetic neur-
algia requiring narcotics. All patients were treated with
antiviral medications. Four were hospitalized and received
acyclovir intravenously, of whom 2 continued on valacy-
clovir and 1 famciclovir orally. The fourth patient devel-
oped renal insufficiency after one day of acyclovir and
received no further treatment. The remaining 5 patients
were treated orally, 4 with valacyclovir and 1 with famci-
clovir. One patient was previously immunized against vari-
cella; 5 had documentation of primary varicella disease in
the past. Mean cSLE disease duration at time of HZV
infection was 4.11 yr (± 2.99), and patients were receiving
a mean dose of prednisone 0.6 mg/kg/d (± 0.51) at the
time of infection. Prednisone dose at the time of HZV dif-
fered significantly from the preceding 3 months (p=0.01,
Wilcoxon test). All patients were receiving additional
immunosuppressive therapy: 4 intravenous cyclophospha-
mide, 2 mycophenolate mofetil, and 2 azathioprine at the
time of infection. SLE disease activity as measured by SLE-
DAI at the time of HZV and 6 months prior to infection
demonstrated a significant increase prior to infection
(p=0.04, Wilcoxon test). Other markers of SLE disease
activity were measured, including dsDNA, C3, C4, total
leucocyte count, absolute neutrophil count, absolute lym-
phocyte count, and platelet count in the months prior to
infection and demonstrated no significant change.
Conclusion
cSLE patients are at increased risk for herpes zoster
infections, and in our population were associated with a
recent increase in disease activity and increased gluco-
corticoid use. Depending upon the site and extent of
involvement, it can be associated with significant
morbidity.
Disclosure
Josephine Isgro: None; Deborah M. Levy: None; Philip
LaRussa: None; Lisa F. Imundo: None; Andrew H.
Eichenfield: None.1Morgan Stanley Children’s Hospital of New York Presbyterian, Columbia
University Medical Center, New York, NY, USA
Full list of author information is available at the end of the article
Isgro et al. Pediatric Rheumatology 2012, 10(Suppl 1):A25
http://www.ped-rheum.com/content/10/S1/A25
© 2012 Isgro et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Author details
1Morgan Stanley Children’s Hospital of New York Presbyterian, Columbia
University Medical Center, New York, NY, USA. 2The Hospital for Sick
Children, Toronto, ON, Canada.
Published: 13 July 2012
doi:10.1186/1546-0096-10-S1-A25
Cite this article as: Isgro et al.: Descriptive analysis of herpes zoster in
childhood-onset systemic lupus erythematosus. Pediatric Rheumatology
2012 10(Suppl 1):A25.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Isgro et al. Pediatric Rheumatology 2012, 10(Suppl 1):A25
http://www.ped-rheum.com/content/10/S1/A25
Page 2 of 2
